Advertisement

Pilzinfektionen

  • Constantin E. Orfanos
  • Claus Garbe

Zusammenfassung

Pilze sind ubiquitär in unserer Umwelt vorhandene Organismen. Sie können in die Haut, in das Haar und in die Nägel des Menschen eindringen, ernähren sich mittels Keratinaseaktivität von Eiweißspaltprodukten des Keratins und werden direkt vom Erdreich oder durch Tier-zu-Mensch- bzw. durch Mensch-zu-Mensch-Kontakte übertragen. Pilze vermehren sich in der Regel durch Sporen, die oft in großen Mengen gebildet werden. Aufgrund der geringen Größe (5 – 25 μm) werden Pilzsporen über weite Strecken durch die Luft transportiert („airborne“). Sie werden inhaliert und können allergische Reaktionen der oberen und unteren Luftwege hervorrufen, einschließlich Asthma und Rhinitis (Aspergillus, Cladosporium), oder aber Infektionen der Lunge als erstem Manifestationsorgan.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Honig K, Wortham C, Zamani K et al. (1993) Terfenadin-Ketoconazol interaction: pharmacokinetic and electrokardiographic consequences. J Am Med Assoc 269: 1513–1531CrossRefGoogle Scholar
  2. Woosley R, Chen Y, Freiman J et al. (1993) Mechanism of the cardiotoxic action of terfenadin. J Am Med Assoc 269: 1532–1549CrossRefGoogle Scholar

Literatur

  1. Anaissie E, Paetznick V, Proffitt R et al. (1991) Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 10: 665–668PubMedCrossRefGoogle Scholar
  2. Brajburg J, Powderly W, Kobayashi G, Medoff G (1990) Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 34:183–138CrossRefGoogle Scholar
  3. Caillot D, Chavanet P, Casanovas O et al. (1992) Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis 11:722–725PubMedCrossRefGoogle Scholar
  4. Caillot D, Casanovas O, Solary E et al. (1993) Efficacy and tolerance of an amphotericin B lipid (Intralipid®) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 31: 161–169PubMedCrossRefGoogle Scholar
  5. Chavanet PY, Garry I, Charlier N et al. (1992) Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 305:921–925CrossRefGoogle Scholar
  6. Christiansen K, Bernard E, Gold J, Armstrong D (1985) Distribution and activity of amphotericin B in humans. J Infect Dis 152:1037–1043PubMedCrossRefGoogle Scholar
  7. Davidson RN, Croft SL, Scott A et al. (1991) Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337:1061–1062PubMedCrossRefGoogle Scholar
  8. Elewski BE, Ogawa H (eds) (1999) Antifungal therapy beyond the year 2000. Br J Dermatol 141; Suppl 56:1–40Google Scholar
  9. Gallis H, Drew R, Pickard W (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308–326PubMedCrossRefGoogle Scholar
  10. Janoff AS, Boni LT, Popescu MC et al. (1988) Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Nat Acad Sci USA 85: 6122–6126PubMedCrossRefGoogle Scholar
  11. Juliano RL, Christopher W, Grant M et al. (1987) Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 31:1–11PubMedGoogle Scholar
  12. Kan V, Bennett J, Amantea M et al. (1991) Comparative safety, tolerance and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 164:418–422PubMedCrossRefGoogle Scholar
  13. Kirsh R, Goldstein R, Tarloff J et al. (1988) An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 158:1065–1070PubMedCrossRefGoogle Scholar
  14. Meunier F, Prentice HG, Ringden O (1991) Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 28 [Suppl B]: 83–91PubMedCrossRefGoogle Scholar
  15. Moreau P, Milpied N, Fayette N et al. (1992) Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid® compared with conventional aamphotericin B in neutropenic patients. J Antimicrob Chemother 30:535–541PubMedCrossRefGoogle Scholar
  16. Ringden O, Meunier F, Tollemar J et al. (1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 28 [Suppl B]: 73–82PubMedCrossRefGoogle Scholar

Literatur

  1. Anaissie E, Bodey GP, Kantarjan H et al. (1991) Fluconazol therapy for chronic disseminated candidosis in patients with leucemia and prior amphotericin B therapy. Am J Med 91:142–150PubMedCrossRefGoogle Scholar
  2. Cauwenbergh G, Degreef H, Heykants J et al. (1988) Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 18: 263–268PubMedCrossRefGoogle Scholar
  3. Clissold SP, Heel RC (1986) Tiokonazole: revision of antifungal activity and therapeutic use in superficial mycosis. Drugs 31:1–22CrossRefGoogle Scholar
  4. Coldiron BM, Manders SM (1991) Persistent Candida intertrigo treated with fluconazole. Arch Dermatol 127:165–166PubMedCrossRefGoogle Scholar
  5. De Bersaques J, Bjerke JR, Borelli S et al. (1992) Comparison of oral fluconazole and topical clotrimazole in the treatment of fungal infections of the skin: european and american experience. Int J Dermatol 31 [Suppl 2]: 21–26CrossRefGoogle Scholar
  6. De Cuyper C, Amblard P, Austad J et al. (1992) Noncomparative study of fluconazole in the treatment of patients with common fungal infections of the skin. Int J Dermatol 31 [Suppl 2]: 17–20Google Scholar
  7. Degreef H (1992) The treatment of superficial skin infections caused by dermatophytes. In: Borgers M, Hay R, Rinaldi MG (eds) Current topics in medical mycology. Springer, Berlin Heidelberg New York Tokyo, pp 189–206CrossRefGoogle Scholar
  8. DeWit S, Goossens H, Weerts D et al. (1989) Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1:746–748PubMedCrossRefGoogle Scholar
  9. Faergemann J, Laufen H (1993) Levels of fluconazole in serum, stratum corneum,epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exper Dermatol 18:102–106CrossRefGoogle Scholar
  10. Fischbein A, Haneke E, Lacner K et al. (1992) Comparative evaluation of oral fluconazole and oral ketoconazole in the treatment of fungal infections of the skin. Int J Dermatol 31 [Suppl 2]: 12–16Google Scholar
  11. Galgiani JN (1990) Fluconazole, a new antifungal agent. Ann Intern Med 113:117–119CrossRefGoogle Scholar
  12. Hay RJ (1988) Fluconazol in the treatment of patients with chronic mucocutaneous candidosis. Br J Dermatol 119: 683–685PubMedCrossRefGoogle Scholar
  13. Hay RJ (1992) Treatment of dermatomycoses and onychomycoses — state of the art. Clin Exp Dermatol 17: 2–5PubMedCrossRefGoogle Scholar
  14. Hay RJ, Clayton YM, Moore MK et al. (1988) An evaluation of itraconazole in the treatment of onychomycosis. Br J Dermatol 119:359–366PubMedCrossRefGoogle Scholar
  15. Kaufman CA, Bradley SF, Ross SC et al. (1991) Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 8:137–141CrossRefGoogle Scholar
  16. Larsen RA (1991) Azoles and AIDS. J Infect Dis 162:727–730CrossRefGoogle Scholar
  17. Lyman CA, Walsh TJ (1992) Systemically administered antifungal agents. Drugs 44:9–35PubMedCrossRefGoogle Scholar
  18. Sanguineti A, Carmichael K, Campbell K (1993) Fluconazole-resistent Candida albicans after long-term suppressive therapy. Arch Intern Med 153:1122–1124PubMedCrossRefGoogle Scholar
  19. Saul A, Bonifaz A (1990) Itraconazol in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol 23 [Suppl]: 554–558PubMedCrossRefGoogle Scholar
  20. Tebbe B, Boyvat A, Geilen ChC et al. (1996) Klinische Fluconazol- und Itraconazol-Resistenz einer orogastrointestinalen Kandidose bei einem Patienten mit AIDS. Hautarzt 47:136–139PubMedCrossRefGoogle Scholar
  21. Walsoe I, Stangerup M, Svejgaard E (1990) Itraconazole in onychomycosis. Acta Derm Venereol (Stockh) 70:137–140Google Scholar

Literatur

  1. Allen HB, Honig PJ, Leyden JJ et al. (1982) Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics 69: 81–83PubMedGoogle Scholar
  2. Bergstresser PR, Elewski B, Hanifin J et al. (1993) Topical terbinafine and clotrimazole in interdigital tinea pedis. A multicenter comparison of cure and relapse rates with 1- and 4week treatment regiments. J Am Acad Dermatol 28: 648–651PubMedCrossRefGoogle Scholar
  3. Bourlond A, Lachapelle JM, Aussems J et al. (1989) Doubleblind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 28: 410–414PubMedCrossRefGoogle Scholar
  4. Clissold SP, Heel RC (1996) Tiokonazole: revision of antifungal activity and therapeutic use in superficial mycosis. Drugs 31:1–22Google Scholar
  5. Degreef H (1992) The treatment of superficial skin infections caused by dermatophytes. In: Borgers M, Hay R, Rinaldi MG (eds) Current topics in medical mycology. Springer, Berlin Heidelberg New York, pp 189–206CrossRefGoogle Scholar
  6. Gan VN, Petruska M, Ginsburg CM (1987) Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatr Infect Dis J 6: 46–49PubMedCrossRefGoogle Scholar
  7. Ginsburg CM, McCracken GH Jr, Petruska M et al. (1983) Effect of feeding on bioavailability of griseofulvin in children. J Pediatr 102:309–311PubMedCrossRefGoogle Scholar
  8. Ginsburg GM, Gan VN, Petruska M (1987) Randomized controlled trial of intralesional corticosteroid and griseofulvin vs griseofulvin alone for treatment of kerion. Pediatr Infect Dis J 6:1084–1087PubMedGoogle Scholar
  9. Hay RJ (1992) Treatment of dermatomycoses and onychomycoses — state of the art. Clin Exp Dermatol 17: 2–5PubMedCrossRefGoogle Scholar
  10. Holmberg K (1986) In vitro assessment of antifungal drug resistance. Acta Derm Venereol [Suppl] 121:131–138Google Scholar
  11. Jung EG, Bisco A, Azzollini E et al. (1988) Fenticonazol cream once daily in dermatomycosis, a double-blind controlled trial versus bifonazole. Dermatologica 177:104–108PubMedCrossRefGoogle Scholar
  12. Korting HC, Rosenkranz S (1981) In vitro susceptibility of dermatophytes from Munich to griseofulvin, miconazole and ketoconazole. Mycoses 33:136–139Google Scholar
  13. Lambert DR, Siegle RJ, Camisa C (1989) Griseofulvin and ketokonazole in the treatment of dermatophyte infections. Int J Dermatol 28:300–304PubMedCrossRefGoogle Scholar
  14. Legendre R, Esola-Macre J (1990) Itraconazole in the treatment of tinea capitis. J Am Acad Dermatol 23: 559–560PubMedCrossRefGoogle Scholar
  15. Lesher JL, Smith JG (1987) Antifungal agents in dermatology. J Am Acad Dermatol 17:383–396PubMedCrossRefGoogle Scholar
  16. Lyman CA, Walsh TJ (1992) Systemically administered antifungal agents. Drugs 44:9–35PubMedCrossRefGoogle Scholar
  17. Macura AB (1991) Fungal resistance to antimycotic drugs: a growing problem. Int J Dermatol 30:181–183PubMedCrossRefGoogle Scholar
  18. Macura AB (1993) Dermatophyte infections. Int J Dermatol 32:313–323PubMedCrossRefGoogle Scholar
  19. Nyawaldo JO, Boire M (1988) Single dose and intermittent griseofulvin regimens in the treatment of tinea capitis in Kenya. Mycoses 31: 229–234CrossRefGoogle Scholar
  20. Saul A, Bonifaz A (1990) Itraconazole in common dermatophyte infections of the skin. Fixed treatment schedules. J Am Acad Dermatol 23:554–558PubMedCrossRefGoogle Scholar
  21. Savin RC, Zaias N (1990) Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. J Am Acad Dermatol 23:804–807PubMedCrossRefGoogle Scholar
  22. Tanz RR, Hebert AA, Esterly NB (1988) Treating tinea capitis: should ketoconazole replace griseofulvin? J Pediatr 112: 987–991PubMedCrossRefGoogle Scholar
  23. Walsoe I, Stangerup M, Svejgaard E (1990) Itraconazole in onychomycosis. Acta Derm Venereol 70:137–140PubMedGoogle Scholar

Literatur

  1. André J, Achten G (1987) Onychomycosis. Int J Dermatol 26: 481–490CrossRefGoogle Scholar
  2. Bergstresser PR, Elewski B, Hanifin J et al. (1993) Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter-comparison of cure and relapse rates with 1- und 4-week treatment regimen. J Am Acad Dermatol 28: 648–651PubMedCrossRefGoogle Scholar
  3. Cauwenbergh G, Degreef H, Heykants J et al. (1988) Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 18: 263–268PubMedCrossRefGoogle Scholar
  4. De Doncker P, Decroix J, Piérard GE et al. (1996) Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 132:34–41PubMedCrossRefGoogle Scholar
  5. Del Palacio A, López-Gómez S, Moreno-Palancar P et al. (1989) A clinical double blind trial comparing amorolfine cream 0.5% (Ro 14–4767) with bifonazole cream 1% in the treatment of dermatomycoses. Clin Exper Dermatol 14:141–144CrossRefGoogle Scholar
  6. Del Palacio A, López-Gómez S, Gimeno C et al. (1991) A randomized comparative study: amorolfine (cream 0.125%, 0.25% and 0.5%) in dermatomycoses. J Dermatol Treat 1: 299–303CrossRefGoogle Scholar
  7. Elewski BE, Ogawa H (eds) (1999) Antifungal therapy beyond the year 2000. Br J Dermatol 144; Suppl 56:1–40Google Scholar
  8. Goodfield MJD (1992) Short duration therapy with terbinafine for dermatophyte onychomycosis: a multi-center trial. Br J Dermatol 129 [Suppl 39]: 33–35CrossRefGoogle Scholar
  9. Gupta AK, Scher RK (1998) Oral antifungal agents for onychomycosis. Lancet 351:541–542PubMedCrossRefGoogle Scholar
  10. Hay RJ (ed) (1992) Amorolfine, a breakthrough in topical antimycotic therapy. Dermatology 184 [Suppl 1]: 1–30Google Scholar
  11. Hay RD, Nishikawa T (eds) (1998) Lamisil®: A global standard for fungal infections in Dermatology. J Dermatol Treatm 9; Suppl 1: S1–S35Google Scholar
  12. Hay RJ, Baran R, Moore MK, Wilkinson JD (1988) Candida onychomycosis: an evaluation of the role of Candida spp. in nail disease. Br J Dermatol 118:47–58PubMedCrossRefGoogle Scholar
  13. Hay RJ, Clayton YM, Moore MK et al. (1988) An evaluation of itraconazole in the treatment of onychomycosis. Br J Dermatol 119:359–366PubMedCrossRefGoogle Scholar
  14. Hay RJ, Logan RA, Moore MK et al. (1991) A comparative study of terbinafme vs griseofulvin in the treatment of „dry type“ dermatophyte infections. J Am Acad Dermatol 24:243–246PubMedCrossRefGoogle Scholar
  15. Lowe G, Green C, Jennings P (1993) Hepatitis associated with terbinafin treatment. Br Med J 306:248CrossRefGoogle Scholar
  16. Nolting SK (1984) Non-traumatic removal of the nail and simultaneous treatment of onychomycosis. Dermatolo-gica 169 [Suppl 1]: 117–120CrossRefGoogle Scholar
  17. Nolting S, Semig G, Friedrich HK et al. (1992) Double blind comparison of amorolfine and bifonazole in the treatment of dermatomycoses. Clin Exp Dermatol 17: 8–12CrossRefGoogle Scholar
  18. Nolting S, Reinel D, Semig G et al. (1993) Amorolfine spray in the treatment of foot mycoses (a dose-finding study). Br J Dermatol 129:170–174PubMedCrossRefGoogle Scholar
  19. Piérard GE, Arrese-Estrada J, Piérard-Franchimont C (1993) Treatment of onychomycosis. Traditional approaches. J Am Acad Dermatol 29:41–45CrossRefGoogle Scholar
  20. Polak A (1988) Mode of action of morpholine derivatives. Ann NY Acad Sci 544: 221–228PubMedCrossRefGoogle Scholar
  21. Roseeuw D, De Doncker P (1993) New approaches to the treatment of onychomycosis. J Am Acad Dermatol 29: 45–50CrossRefGoogle Scholar
  22. Saul A, Bonifaz A (1990) Itraconazol in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol 23 [Suppl]: 554–558PubMedCrossRefGoogle Scholar
  23. Schatz F, Bräutigam M, Dobrowolski E et al. (1995) Nail incorporation kinetics of terbinafme in onychomycosis patients. Clin Exp Dermatol 20:377–383PubMedCrossRefGoogle Scholar
  24. Schroeff JG van der, Circel PKS, Crijus MP (1992) A randomized treatment duration-finding study of terbinafme in onychomycosis. Br J Dermatol 125 [Suppl 39]: 36–39CrossRefGoogle Scholar
  25. Tosti A, Piraccini BM, Stinchi C (1996) Treatment of dermatophyte nail infections: an open randomised study comparing intermittent terbinafme therapy with continuous terbinafme therapy and itraconazole therapy. J Am Acad Dermatol 34:595–600PubMedCrossRefGoogle Scholar
  26. Villars V, Jones TC (1989) Clinical efficacy and tolerability of terbinafme (Lamisil®); a new topical and systemic fungicidal long for treatment of dermatomycoses. Clin Exper Dermatol 14:124–127CrossRefGoogle Scholar
  27. Walsoe I, Stangerup M, Svejgaard E (1990) Itraconazole in onychomycosis. Acta Derm Venereol 70:137–140PubMedGoogle Scholar
  28. Willemsen M, De Doncker P, Willems J et al. (1993) Post-treatment itraconazole levels in the nail: new implications for treatment of onychomycosis. J Am Acad Dermatol 26: 731–735CrossRefGoogle Scholar
  29. Zaias N (1990) Management of onychomycosis with oral terbinafme. J Am Acad Dermatol 23: 810–812PubMedCrossRefGoogle Scholar
  30. Zaias N, Serrano L (1989) The successful treatment of finger Trichophyton rubrum onychomycosis infection with oral terbinafme. Clin Exp Dermatol 14:120–123PubMedCrossRefGoogle Scholar
  31. Zang M (1989) L’amorolfine: résultats cliniques préliminaires en dermatologie. Bull Soc Fr Mycol Med 1:17–22Google Scholar

Literatur

  1. Calhoun DL, Waskin H, White MP et al. (1991) Treatment of systemic sporotrichosis with ketokonazole. Rev Infect Dis 13:47–51PubMedCrossRefGoogle Scholar
  2. Campos P, Arenas R, Coronado H (1994) Epidemic cutaneous sporotrichosis. Int J Dermatol 33:38–41PubMedCrossRefGoogle Scholar
  3. Castro LGM, Belda W Jr, Cuce LC, Sampaio SA, Stevens DA (1993) Successful treatment of sporotrichosis with oral fluconazole: a report of three cases. Br J Dermatol 128: 352–356PubMedCrossRefGoogle Scholar
  4. Hull PR, Vismer HF (1992) Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 126:51–55PubMedCrossRefGoogle Scholar
  5. Kauffman CA (1995) Old and new therapies for sporotrichosis. Clin Infect Dis 21:981–985PubMedCrossRefGoogle Scholar
  6. Mercurio MG, Elewski BE (1993) Therapy of sporotrichosis. Semin Dermatol 12:285–289PubMedGoogle Scholar
  7. Purvis RS, Diven DG, Drechsel RD et al. (1993) Sporotrichosis presenting as arthritis and subcutaneous nodules. J Am Acad Dermatol 28: 879–884PubMedCrossRefGoogle Scholar
  8. Restrepo A, Robledo A, Gomez I et al. (1986) Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 122:413–417PubMedCrossRefGoogle Scholar
  9. Rotowa NA, Shadomy HJ, Shadomy S (1990) In vitro activities of polyene and imidazol antifungal agents in unusual opportunistic fungal pathogens. Mycoses 33: 203–211PubMedGoogle Scholar
  10. Shaw JC, Levinson W, Montanaro A (1989) Sporotrichosis in the acquired immunodeficiency syndrome. J Am Acad Dermatol 21:1145–1147PubMedCrossRefGoogle Scholar
  11. Viviani MA, Tortorano AM, Pagano A et al. (1990) European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 23:587–593PubMedCrossRefGoogle Scholar

Literatur

  1. Chermsirivathana S, Bunyaratavej K, Pupaibul K (1979) The treatment of chromomycosis with 5-fluorocytosine. Int J Dermatol 18:377–379PubMedGoogle Scholar
  2. Defaveri J, Graybill JR (1990) Treatment of chronic murine chromoblastomycosis with the triazole SCH 39304. Am J Trop Med Hyg 42: 601–606PubMedGoogle Scholar
  3. Heyl T (1985) Treatment of chromomycosis with itraconazole. Br J Dermatol 112:728–729PubMedCrossRefGoogle Scholar
  4. Lubritz RR (1977) Cryosurgery for benign and malignant skin lesions: treatment with a new instrument. South Med J 69:1401–1405CrossRefGoogle Scholar
  5. McBurney EI (1982) Chromoblastomycosis treatment with ketoconazole. Cutis 30:746–748PubMedGoogle Scholar
  6. McGinnis MR (1983) Chromoblastomycosis and phaeohy-phomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol 8:1–16PubMedCrossRefGoogle Scholar
  7. Nishimoto K, Yoshimura S, Honma K (1984) Chromomycosis spontaneously healed. Int J Dermatol 23: 408–410PubMedCrossRefGoogle Scholar
  8. Silber JG, Gombert ME, Green KM et al. (1983) Treatment of chromomycosis with ketoconazole and 5-fluorocytosine. J Am Acad Dermatol 8:236–238PubMedCrossRefGoogle Scholar
  9. Tagami H, Ginoza M, Imaizumi S et al. (1984) Successful treatment of chromomycosis with topical heat therapy. J Am Acad Dermatol 10: 615–619PubMedCrossRefGoogle Scholar
  10. Yanase K, Yamada M (1978) Pocket-warmer therapy of chromomycosis. Arch Dermatol 114:1095PubMedCrossRefGoogle Scholar

Literatur

  1. Böhler K, Metze D, Poitschek C et al. (1990) Cutaneous aspergillosis. Clin Exp Dermatol 15:446–450PubMedCrossRefGoogle Scholar
  2. Bossche H van den, Marichal P, Willemsens G et al. (1990) Saperconazole: a selective inhibitor of the cytochrome P450 dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes. Mycosis 33:335–352Google Scholar
  3. Cockerell CJ (1990) Cutaneous manifestations of HIV infection other than Kaposi’s sarcoma. J Am Acad Dermatol 22:1260–1269PubMedCrossRefGoogle Scholar
  4. Denning DW, Tucker RM, Hanson LH (1990) Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis. J Am Acad Dermatol 23: 602–607PubMedCrossRefGoogle Scholar
  5. Dupont B (1990) Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 23: 607–614PubMedCrossRefGoogle Scholar
  6. Googe PD, De Coste SD, Herold WH et al. (1989) Primary cutaneous aspergillosis mimicking dermatophytosis. Arch Pathol Lab Med 113:1284–1286PubMedGoogle Scholar
  7. Harmon CB, Su D, Peters MS (1993) Cutaneous aspergillosis complicating pyoderma gangrenosum. J Am Acad Dermatol 29:656–658PubMedCrossRefGoogle Scholar
  8. Khardori N, Hayat S, Rolston K (1989) Cutaneous rhizopus and aspergillus infections in five patients with cancer. Arch Dermatol 125:952–956PubMedCrossRefGoogle Scholar
  9. Meunier F (1990) Fluconazole treatment of fungal infections in the immunocompromised host. Semin Oncol 17 [Suppl 6]:19–23PubMedGoogle Scholar
  10. Staib F, Bennhold I, Voigt HW et al. (1987) Amphotericin B und Fluzytosin-Therapie bei Aspergillus-Pneumonie und akutem Nierenversagen. Klin Wochenschr 65:40–47PubMedCrossRefGoogle Scholar
  11. Vivani MA, Tortorano AM, Langer M (1989) Experience with itraconazole in cryptococcosis and aspergillosis. J Infect 18:151–165CrossRefGoogle Scholar

Literatur

  1. Barfield L, Iacobelli D, Hashimoto K (1988) Secondary cutaneous cryptococcosis: case report and review of 22 cases. J Cutan Pathol 15:385–392PubMedCrossRefGoogle Scholar
  2. Calck MV, Motte S, Serruys E (1988) Cryptococcal anal ulceration in a patient with AIDS. Am J Gastroenterol 83: 1306–1308PubMedGoogle Scholar
  3. Chuck SL, Sande MA (1989) Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 321:794–799PubMedCrossRefGoogle Scholar
  4. Cooper CM, Gordon DL, Reid C, Philpot CR (1992) Cutaneous cryptococcosis: recurrence following oral fluconazole treatment. Austral J Dermatol 33:93–96CrossRefGoogle Scholar
  5. Denning DW, Tucker RM, Hanson LH (1990) Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis. J Am Acad Dermatol 23: 602–607PubMedCrossRefGoogle Scholar
  6. Iacobelli FW, Jacobs MI, Cohen RP (1979) Primary cutaneous cryptococcosis. Arch Dermatol 115:984–985CrossRefGoogle Scholar
  7. Jones C, Orengo I, Rosen T (1990) Cutaneous cryptococcosis simulating Kaposi’s sarcoma in the AIDS. Cutis 47: 163–167Google Scholar
  8. Manrique P, Mayo J, Alvarez JA et al. (1992) Polymorphous cutaneous cryptococcosis: nodular, herpes-like and molluscum-like lesions in a patient with the acquired immunodeficiency syndrome. J Am Acad Dermatol 127:1848–1849Google Scholar
  9. Meunier F (1990) Fluconazole treatment of fungal infections in the immunocompromised host. Semin Oncol 17 [Suppl 6]:19–23PubMedGoogle Scholar
  10. Poizot-Martin I, Grob JJ, Fournerie JR et al. (1991) Crypto-coccose cutanée a forme de molluscum contagiosum an cours de SIDA. Ann Dermatol Venereol 118:29–32PubMedGoogle Scholar
  11. Shuttleworth D, Philpot CM, Knight AG (1989) Cutaneous cryptococcosis: treatment with oral fluconazole. Br J Dermatol 120: 683–687PubMedCrossRefGoogle Scholar
  12. Staib F, Seibold M (1988) Mycologic diagnostic assessment of the efficacy of amphotericin B + flucytosine to control cryptococcus neoformans in AIDS patients. Mycoses 31: 175–186PubMedCrossRefGoogle Scholar
  13. Sugar AM, Saunders C (1988) Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with AIDS. Am J Med 85:481–489PubMedCrossRefGoogle Scholar
  14. Vivani MA, Tortorano AM, Langer M (1989) Experience with itraconazole in cryptococcosis and aspergillosis. J Infect 18:151–165CrossRefGoogle Scholar

Literatur

  1. Dijkstra JWE (1989) Histoplasmosis. Dermatol Clin 7:251–257Google Scholar
  2. Johnson PC, Khardori, Najiar F et al. (1988) Progressive disseminated histoplasmosis in patients with AIDS. Am J Med 85:152–158PubMedCrossRefGoogle Scholar
  3. Krunic AL, Calonje E, Jeftovic D et al. (1995) Primary localized cutaneous histoplasmosis in a patient with acquired immundeficiency syndrome. Int J Dermatol 34:558–562PubMedCrossRefGoogle Scholar
  4. Kurtin PJ, McKinsey DS, Gupta MR (1990) Histoplasmosis in patients with AIDS. Am J Clin Pathol 93:367–372PubMedGoogle Scholar
  5. Mandell W, Goldberg DM, Neu HC (1986) Histoplasmosis in patients with the acquired immune deficiency syndrome. Am J Med 81: 974–978PubMedCrossRefGoogle Scholar

Literatur

  1. Catanzaro A, Fierer J, Friedman PJ (1990) Fluconazole in the treatment of persistent coccidioidomycosis. Chest 97: 666–669PubMedCrossRefGoogle Scholar
  2. Galgiani JN (1983) Ketoconazole in the treatment of coccidioidomycosis. Drugs 26:355–363PubMedCrossRefGoogle Scholar

Literatur

  1. Bakos L, Kronfeld M, Hampe S et al. (1989) Disseminated paracoccidioidomycosis with skin lesions in a patient with acquired immune deficiency syndrome. J Am Acad Dermatol 20: 854–855PubMedCrossRefGoogle Scholar
  2. Goldani LZ, Martinez R, Landell GA et al. (1989) Paracoccidioidomycosis in a patient with acquired immundeficiency syndrome. Mycopathologia 195:71–75CrossRefGoogle Scholar
  3. Negroni R (1993) (1993) Paracoccidioidomycosis (south american blastomycosis, Lutz’s mycosis). Int J Dermatol 32: 847–859PubMedCrossRefGoogle Scholar
  4. Restrepo-Moreno A (1990) Paracoccidioides brasiliensis. In: Mandel GL, Douglas RG, Bennett JE (eds) Principles and practice of infectious diseases, 3rd edn. Churchill-Livingstone, New York, pp 2028–2031Google Scholar
  5. Padilha-Gonsalves A (1987) Paracoccidioidomycosis. In: Orfanos CE, Stadler R, Gollnick H (eds) Dermatology in five continents. Springer, Berlin Heidelberg New York Tokyo, pp 356–360Google Scholar

Literatur

  1. Blume U, De Almeida HL, Seibold M et al. (1992) Mucocutaneous blastomycosis with epididymitis and orchitis blastomycetica: successful long-term treatment with ketoconazole. Eur J Dermatol 2:31–34Google Scholar
  2. Dismukes WE, Cloud G, Bontes C et al. (1985) Treatment of blastomycosis and histoplasmosis with ketoconazole. Ann Intern Med 103: 861CrossRefGoogle Scholar
  3. Drouhet E, Dupont B (1983) Laboratory and clinical assessment of ketoconazole in deepseated mycosis. Am J Med 74:30–57PubMedCrossRefGoogle Scholar
  4. Klein BS (1990) North American blastomycosis. In: Jacobs PH, Nall L (eds) Antifungal therapy. Dekker, New York, p 178Google Scholar
  5. Truhan AP, Roenigk HH (1987) Blastomycosis in a patient with psoriasis: treatment with ketoconazole. Cutis 39: 413–417PubMedGoogle Scholar

Literatur

  1. Assaf C, Goerdt S, Seibold M et al. (2000) Cutaneous hyalohyphomycosis. Lancet 356:1185PubMedCrossRefGoogle Scholar
  2. Baruzzi RG, Rodriguez DA, Michalany NS et al. (1989) Squamous cell carcinoma and lobomycosis (Jorge Lobo’s disease). Int J Dermatol 28:183–185PubMedCrossRefGoogle Scholar
  3. Burges GE, Walls CT, Maize JC (1987) Subcutaneous phaehyphomycosis caused by Exserophilum rostratum in an immunocompetent host. Arch Dermatol 123:1346–1350PubMedCrossRefGoogle Scholar
  4. Chuan MT, Wu MC (1995) Subcutaneous phaehyphomycosis caused by Exophiala Jeanselmei: successful treatment with itraconazole. Int J Dermatol 34:563–566PubMedCrossRefGoogle Scholar
  5. Coldiron BM, Wiley EL, Rinaldi MG (1990) Cutaneous phaehyphomycosis caused by a rare fungal pathogen Hormonema dermatioides: successful treatment with keto-konazole. J Am Acad Dermatol 23:363–367PubMedCrossRefGoogle Scholar
  6. Krishnan KN (1979) Clinical trial of diaminodiphenylsulfone (DDS) in nasal and nasopharyngeal rhinosporidiosis. Laryngoscope 89: 291–295Google Scholar
  7. Lawrence DN, Ajello N (1986) Lobomycosis in Western Brazil: report of a clinical trial with ketokonazol. Am J Trop Med Hyg 35:162–166PubMedGoogle Scholar
  8. Mark Ming-Long Hsu, Yu-Yun Lee J (1993) Cutaneous and subcutaneous phaeohyphomycosis caused by Exserophilum rostratum. J Am Acad Dermatol 28:340–344PubMedCrossRefGoogle Scholar
  9. Noel SB, Greer DL, Abadie SH et al. (1988) Primary cutaneous phaehyphomycosis. Report of 3 cases. J Am Acad Dermatol 18:1023–1030PubMedCrossRefGoogle Scholar
  10. McGinnis MR (1983) Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol 8:1–16PubMedCrossRefGoogle Scholar
  11. Rodriguez-Toro G (1993) Lobomycosis. Int J Dermatol 32: 324–332CrossRefGoogle Scholar
  12. Rotowa NA, Shadomy HJ, Shadomy S (1990) In vitro activities of polyene and imidazol antifungal agents in unusual opportunistic fungal pathogens. Mycoses 33: 203–211PubMedGoogle Scholar
  13. Sharkey PK, Graybill JR, Hanson LH et al. (1990) Itrakonacole treatment of phaeohyphomycosis. J Am Acad Dermatol 23:577–586PubMedCrossRefGoogle Scholar
  14. Silva D (1978) Traitement de la maladie de Jorge Lobo par la clofazimine (B 663). Bull Soc Pathol Exot 71:409–412Google Scholar
  15. Tyzing SK, Lee PC, Walsh P et al. (1989) Papular protothecosis of the chest. Immunologic evaluation and treatment with a combination of oral tetracycline and topical Amphotericin B. Arch Dermatol 125:1249–1252CrossRefGoogle Scholar

Weiterführende Literatur zu Kapitel 2

  1. Elewski BE (1992) Cutaneous fungal infections. Igaku-Shoin, New York Tokyo, pp 1–255Google Scholar
  2. Elewski BE, Ogawa H (eds) (1999) Antifungal therapy beyond the year 2000. Br J Dermatol 141; Suppl 56:1–40Google Scholar
  3. El Sheikh Mahgoub (ed) (1989) Tropical mycosis. Janssen, pp 1–226Google Scholar
  4. Hay RJ (1988) Fortschritte in der lokalen antimykotischen Therapie, Springer, Berlin Heidelberg New York Tokyo, S 1–143CrossRefGoogle Scholar
  5. Gabard B, Elsner P, Surber C et al. (eds) (2000) Dermato-pharmacology of topical preparations: a product development-oriented approach. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  6. Hay RJ (1990) Fungal infections in the kinetics and the role of oral therapy. Br J Clin Pract 44 [Suppl 71]: 1–123Google Scholar
  7. Iwata K, Bossche H van den (1985) In vitro and in vivo evaluation of antifungal agents. Elsevier, Amsterdam, pp 1–305Google Scholar
  8. Maddin S, Scher RK (1993) Superficial fungal infections in evolution. Focus on the systemic therapeutic options for the therapy of onychomycosis. J Am Acad Dermatol 29: 35–54CrossRefGoogle Scholar
  9. Merk H (1993) Antimykotika, Teil I und II. Hautarzt 44: 191–198, 257–266PubMedGoogle Scholar
  10. Petranyi G, Ryder NS, Stütz A (1984) Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalence epoxidase. Science 224:1239–1241PubMedCrossRefGoogle Scholar
  11. Reitmeier G (1991) Topische Antimyzetika-Therapie in der Dermatologie. In: Hornstein OP, Meinhof W (Hrsg) Fortschritte der Mykologie. Perimed, Erlangen, S 98–106Google Scholar
  12. Seebacher C (2001) Dermatomykosen. Grundlagen und Therapie. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  13. Stahlmann R, Schulz-Schalge T, Lode H (1991) Wirkungsweise und Pharmakokinetik neuerer Azol-Antimykotika. In: Staib F, Huhn D (Hrsg) Pilzinfektionen bei abwehrgeschwächten Patienten. Springer, Berlin Heidelberg New York Tokyo, pp 73–86CrossRefGoogle Scholar
  14. Staib F (1991) Zunehmende Inzidenz tiefer Mykosen — Epidemiologie, Diagnostik und Therapie. Bundesgesund 34: 212–216Google Scholar
  15. Staib F, Huhn D (1991) Pilzinfektionen bei abwehrgeschwächten Patienten. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Constantin E. Orfanos
    • 1
  • Claus Garbe
    • 2
  1. 1.Klinik und Poliklinik für DermatologieUniversitätsklinikum Benjamin Franklin Freie Universität BerlinBerlinDeutschland
  2. 2.Hautklinik und PoliklinikEberhard-Karls-UniversitätTübingenDeutschland

Personalised recommendations